Correlation of molecular alterations with efficacy of everolimus in hormone-receptor–positive (HR+), HER2-negative advanced breast cancer: Preliminary results from BOLERO-2.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. LBA509-LBA509
Author(s):  
Gabriel N. Hortobagyi ◽  
Martine J. Piccart-Gebhart ◽  
Hope S. Rugo ◽  
Howard A. Burris ◽  
Mario Campone ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Hormone Receptor ◽  
Daily News ◽  
Online Supplement ◽  
Molecular Alterations ◽  
Hormone Receptor Positive ◽  
Final Text

LBA509 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Monday, June, 3, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

New insights into the risk of breast cancer in childhood cancer survivors treated with chest radiation: A report from the Childhood Cancer Survivor Study (CCSS) and the Women's Environmental Cancer and Radiation Epidemiology(WECARE) Study.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. CRA9513-CRA9513
Author(s):  
Chaya S. Moskowitz ◽  
Joanne F. Chou ◽  
Suzanne L. Wolden ◽  
Jonine L. Bernstein ◽  
Jyoti Malhotra ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Childhood Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Childhood Cancer Survivors ◽  
Daily News ◽  
Online Supplement ◽  
Radiation Epidemiology ◽  
Childhood Cancer Survivor Study ◽  
Final Text

CRA9513 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA506-LBA506 ◽  
Author(s):  
Andre Robidoux ◽  
Gong Tang ◽  
Priya Rastogi ◽  
Charles E. Geyer ◽  
Catherine A. Azar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Therapy ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Operable Breast Cancer ◽  
Daily News ◽  
Online Supplement ◽  
B 41 ◽  
Final Text

LBA506 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Sunday, June 3, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. CRA1008-CRA1008 ◽  
Author(s):  
G. Thomas Budd ◽  
William E. Barlow ◽  
Halle C. F. Moore ◽  
Timothy J. Hobday ◽  
James A. Stewart ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Daily News ◽  
Online Supplement ◽  
Final Text

CRA1008 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Monday, June, 3, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC followed by paclitaxel (P) plus gemcitabine (G) with DD AC followed by P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA1000-LBA1000
Author(s):  
Sandra M. Swain ◽  
Gong Tang ◽  
Charles E. Geyer ◽  
Priya Rastogi ◽  
James Norman Atkins ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Daily News ◽  
Adjuvant Trial ◽  
Online Supplement ◽  
Node Positive ◽  
Dose Dense ◽  
Final Text ◽  
Positive Breast Cancer

LBA1000 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 5-5 ◽  
Author(s):  
Richard G. Gray ◽  
Daniel Rea ◽  
Kelly Handley ◽  
Sarah Jane Bowden ◽  
Philip Perry ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Early Breast Cancer ◽  
Adjuvant Tamoxifen ◽  
Long Term Effects ◽  
Daily News ◽  
Online Supplement ◽  
Final Text

5 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Sunday, June, 2, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC).

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. LBA500-LBA500 ◽  
Author(s):  
Gunter Von Minckwitz ◽  
Marion Jennifer Procter ◽  
Evandro De Azambuja ◽  
Dimitrios Zardavas ◽  
Adam Knott ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Early Breast Cancer ◽  
Her2 Positive ◽  
Daily News ◽  
Online Supplement ◽  
Big 4 ◽  
Final Text

LBA500 The full, final text of this abstract will be available at abstracts.asco.org at 7:30 AM (EDT) on Monday, June 5, 2017, and in the Annual Meeting Proceedings online supplement to the June 20, 2017, issue of the Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. CRA501-CRA501 ◽  
Author(s):  
A. Tutt ◽  
M. Robson ◽  
J. E. Garber ◽  
S. Domchek ◽  
M. W. Audeh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Parp Inhibitor ◽  
Advanced Breast ◽  
Final Text

CRA501 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. [Table: see text]

Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. CRA3503-CRA3503 ◽  
Author(s):  
Dirk Arnold ◽  
Thierry Andre ◽  
Jaafar Bennouna ◽  
Javier Sastre ◽  
Pia J. Osterlund ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Phase Iii ◽  
Daily News ◽  
Online Supplement ◽  
Previously Treated ◽  
Final Text

CRA3503 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Sunday, June 3, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 3-3 ◽  
Author(s):  
Mathias J. Rummel ◽  
Norbert Niederle ◽  
Georg Maschmeyer ◽  
Andre G. Banat ◽  
Ulrich von Gruenhagen ◽  
...  
Keyword(s):  
Annual Meeting ◽  
Clinical Oncology ◽  
Line Treatment ◽  
First Line ◽  
Daily News ◽  
Online Supplement ◽  
Mantle Cell ◽  
Final Text ◽  
First Line Treatment

3 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Sunday, June 3, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA5002-LBA5002 ◽  
Author(s):  
Eric Pujade-Lauraine ◽  
Felix Hilpert ◽  
Béatrice Weber ◽  
Alexander Reuss ◽  
Andres Poveda ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Recurrent Ovarian Cancer ◽  
Phase Iii ◽  
Daily News ◽  
Phase Iii Trial ◽  
Online Supplement ◽  
Final Text

LBA5002^ The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Saturday, June 2, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.

Sign in / Sign up

Export Citation Format

Share Document